Document is current
Any future updates will be listed below
-
Authors
Maurer, Alexander
Clerici, Giulio
Schaab, Jan A.
Cheng, Phil F.
Mihic-Probst, Daniela
Mader, Cäcilia
Messerli, Michael
Huellner, Martin W.
Dummer, Reinhard
Dimitriou, Florentia
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Received: 3 June 2024
Accepted: 24 September 2024
First Online: 1 October 2024
Declarations
:
: FD receives/received honoraria and travel support from Merck Sharp & Dohme, Bristol-Myers Squibb, Pierre Fabre and Sun Pharma. MH received grants and speaker honoraria from GE Healthcare, a fund by the Alfred and Annemarie von Sick legacy and a grant from the clinical research priority program (CRPP) Artificial Intelligence in Oncological Imaging Network of the University of Zurich. RD has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME, all which took place outside the submitted work. All other authors have declared no conflicts of interest.
: Ethics approval and consent to participate was obtained from the local ethics committee (KEK Zürich, BASEC-Nr. 2022-00551).
: Ethics approval and consent to participate was obtained from the local ethics committee (KEK Zürich, BASEC-Nr. 2022-00551).
